Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 0.002 (0.67%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q4 2021 Marinus Pharmaceuticals Inc Earnings Call Transcript

Mar 21, 2022 / 12:00PM GMT
Release Date Price: €8.1 (-12.90%)
Operator

Greetings, and welcome to the Marinus Pharmaceuticals approval for Quarter and Full Year 2021 Financial Results and Business Update Call. (Operator Instructions)

And now it is my pleasure to introduce your host, Sasha Damouni, Vice President of Corporate Affairs and Investor Relations. You may begin.

Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - VP of Corporate Affairs & IR

Thank you, and good morning, everyone. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; Kimberly McCormick, Senior Vice President of Regulatory Affairs; Christy Shafer, Chief Commercial Officer; and Steve Pfanstiel, Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot